Company intelligence / Profile preview

Lexaria CanPharm

Kelowna, British Columbia, Canada

Ownership: Private
Development stage: Other

Overview

Lexaria CanPharm's key clinical result is the demonstration of DehydraTECH's superior bioavailability, faster onset, and improved tolerability compared to standard cannabis formulations, including successful commercial application and technology licensing (now in the portfolio of Hill Street Beverage Company following asset acquisition)

Therapeutic areas: OtherPsychiatry
Modalities: Small moleculeBiologic (for cannabinoids)Lipid nanoparticle delivery therapy (via DehydraTECH platform)
Industry: Non-Drug Biotech

Partnerships

Hill Street Beverage Company (acquirer; exclusive perpetual rights for non-pharma cannabis products)CBD product manufacturers (via Lexaria Hemp Corp.) (related through license extension)

Beyond the preview

Go deeper on Lexaria CanPharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lexaria CanPharm.

Explore the full profile